UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 547

Sortiert nach

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2017-07, Vol.28 (suppl_4), p.iv1-iv21

2017

Link zum Volltext

Verfügbarkeit prüfen

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2016-09, Vol.27 (suppl 5), p.v1-v27

2016

Link zum Volltext

Verfügbarkeit prüfen

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi89-vi98

2013

Link zum Volltext

Verfügbarkeit prüfen

Current status of immune checkpoint inhibition in early-stage NSCLC

Annals of oncology, 2019-08, Vol.30 (8), p.1244-1253

2019

Link zum Volltext

Verfügbarkeit prüfen

Pulmonary carcinoid: a rare thoracic malignancy, a high need for better defined systemic therapy

Annals of oncology, 2015-08, Vol.26 (8), p.1527-1529

Vansteenkiste, J.

2015

Link zum Volltext

Verfügbarkeit prüfen

Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding

Annals of oncology, 2021-12, Vol.32 (12), p.1463-1465

2021

Link zum Volltext

Verfügbarkeit prüfen

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2021-07, Vol.32 (7), p.839-853

2021

Link zum Volltext

Verfügbarkeit prüfen

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development

Annals of oncology, 2012-06, Vol.23 (6), p.1387-1393

2012

Link zum Volltext

Verfügbarkeit prüfen

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Annals of oncology, 2014-08, Vol.25 (8), p.1462-1474

2014

Link zum Volltext

Verfügbarkeit prüfen

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

British journal of cancer, 2010-01, Vol.102 (2), p.301-315

2010

Link zum Volltext

Verfügbarkeit prüfen

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i1-i2

2018

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches

Annals of oncology, 2022-09, Vol.33 (9), p.893-908

2022

Link zum Volltext

Verfügbarkeit prüfen

Will liquid biopsies become our fluid transition to personalized immunotherapy?

Annals of oncology, 2018-01, Vol.29 (1), p.11-13

2018

Link zum Volltext

Verfügbarkeit prüfen

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Annals of oncology, 2022-05, Vol.33 (5), p.466-487

2022

Link zum Volltext

Verfügbarkeit prüfen

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Annals of oncology, 2020-02, Vol.31 (2), p.191-201

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Lung cancer (Amsterdam, Netherlands), 2019-07, Vol.133, p.83-87

2019

Link zum Volltext

Verfügbarkeit prüfen

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Cancer treatment reviews, 2015-06, Vol.41 (6), p.465-475

2015

Link zum Volltext

Verfügbarkeit prüfen

Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC

Annals of oncology, 2018-04, Vol.29 (4), p.789-791

2018

Link zum Volltext

Verfügbarkeit prüfen

Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy

JNCI : Journal of the National Cancer Institute, 2002-08, Vol.94 (16), p.1211-1220

2002

Link zum Volltext

Verfügbarkeit prüfen

Screening and early detection of lung cancer

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x320-x327

2012

Link zum Volltext

Verfügbarkeit prüfen

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

Annals of oncology, 2015-08, Vol.26 (8), p.1734-1740

2015

Link zum Volltext

Verfügbarkeit prüfen

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Scientific reports, 2022-05, Vol.12 (1), p.8342-8342, Article 8342

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

British journal of cancer, 2015-07, Vol.113 (2), p.199-203

2015

Link zum Volltext

Verfügbarkeit prüfen

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Annals of oncology, 2018-08, Vol.29 (8), p.1701-1709

2018

Link zum Volltext

Verfügbarkeit prüfen

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Annals of oncology, 2019-11, Vol.30 (11), p.1686-1688

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 547

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(490)
Mit Volltextzugriff
(507)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(234)
Humans
(202)
Life Sciences & Biomedicine
(202)
Oncology
(135)
Male
(104)
Female
(99)
Biological And Medical Sciences
(86)
Respiratory System
(82)
Medical Sciences
(79)
Middle Aged
(77)
Adult
(74)
Aged
(73)
Lung Neoplasms - Pathology
(72)
Lung Neoplasms - Drug Therapy
(61)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(52)
Pneumology
(49)
Carcinoma, Non-Small-Cell Lung - Pathology
(46)
Tumors Of The Respiratory System And Mediastinum
(45)
Neoplasm Staging
(44)
Lung Cancer
(38)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Current status of immune checkpoint inhibition in early-stage NSCLC

Pulmonary carcinoid: a rare thoracic malignancy, a high need for better defined systemic therapy

Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years

Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches

Will liquid biopsies become our fluid transition to personalized immunotherapy?

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC

Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy

Screening and early detection of lung cancer

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Suchergebnisse filtern